Small-cap pharmaceutical stocks have significantly outperformed their large-cap peers over the past year, with investors increasingly rewarding companies that have lower exposure to commoditised US generics and a stronger presence in niche, high-margin segments.
Among the small-cap names, Bliss GVS Pharma has surged 362% over the past year, while Ind-Swift Laboratories, Sakar Healthcare, Shilpa Medicare and Kwality Pharmaceuticals have jumped 281%, 217%, 149% and 282%, respectively.
In comparison, large-cap pharma stocks have delivered more moderate returns. Sun Pharmaceutical Industries share price gained 14%, Divis Laboratories rose 58%, Torrent Pharmaceuticals advanced 36%, while Zydus Lifesciences gained 12%. Cipla declined 10% during the period.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
Why Are Small-Cap Pharma Stocks Outperforming?
One of the key factors behind the divergence is the difference in business mix. Large pharmaceutical companies continue to have significant exposure to the US generics market, where pricing pressure and intense competition have weighed on growth and margins.
Several smaller companies, meanwhile, have been shifting towards differentiated products, contract development and manufacturing, oncology, peptides and complex injectables. These segments typically offer better pricing power and higher entry barriers than conventional generic drugs.
Additionally, global China+1 strategy has also emerged as a structural opportunity for Indian pharmaceutical companies.
ALSO READ: Reading Between The Lines: IRDAI Eyes Credit Data For Insurance Scores. Where Are The Guardrails?
As global drugmakers look to diversify their supply chains, Indian CDMO and CRDMO companies are positioned to win outsourcing contracts and manufacturing opportunities. The outsourcing opportunity is particularly relevant for companies with niche capabilities, as customers are looking for alternatives to China for APIs, formulations and complex pharmaceutical products.
Another common theme among the outperformers is their focus on specialised therapies and complex products. Companies are increasing their presence in areas such as oncology, peptides and complex injectables, where competition is relatively limited and products can command better pricing.
Patent expiries in cancer drugs could further create opportunities for Indian manufacturers, particularly those capable of developing complex formulations and supplying regulated markets.
Company-Specific Growth Drivers
Bliss GVS Pharma has benefited from its niche dosage-form business, improving profitability and a largely debt-free balance sheet. Capacity expansion has also supported its growth trajectory.
Ind-Swift Laboratories is transitioning towards higher-margin finished dosage-form exports. The company is also moving towards execution of CDMO deals with Viatris, Manx and Arrotex. Its own-brand export mix has increased to around 57%, supporting the potential for margin expansion.
Shilpa Medicare has strengthened its focus on oncology APIs, formulations and biologics. The company has reported record revenue and EBITDA, while formulation sales growth has exceeded 30%. EBITDA margins have expanded to around 28-29%.
ALSO READ: Godfather Of AI Takes On Nvidia's Jensen Huang Playing Down Slowdown Call — 'He Has Trump's Ears'
Kwality Pharmaceuticals is focusing on oncology, injectables and peptides, giving it exposure to high-margin therapeutic segments. Management has also indicated strong growth prospects.
Sakar Healthcare has been benefiting from oncology exports, a strong dossier approval pipeline and new launches in Europe. The company expects EBITDA margins to cross 30% by FY27.
What Could Support the Rally Ahead?
The growth story for smaller pharma companies could remain linked to several structural trends.
The CDMO/CRDMO outsourcing pipeline remains an important growth driver as global pharmaceutical companies diversify their manufacturing base. A weaker rupee could also support export realisations for companies with significant overseas revenue.
At the same time, oncology, peptides and complex injectables are likely to remain key areas of focus, while patent expiries could provide another opportunity by opening up markets for complex generic and specialty products.
The sharp outperformance of small-cap pharma stocks therefore reflects more than just a broad sector rally. The market appears to be rewarding companies with differentiated product portfolios, higher-margin businesses and exposure to structural opportunities such as China+1 and global pharmaceutical outsourcing.
ALSO READ: NSE IPO GMP Signals Muted Listing Tomorrow. Check Details Here
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
